The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Recordati announces that Gedeon Richter Plc. was granted marketing authorization from the European Commission for Reagila (cariprazine), a novel antipsychotic...
Reagila is indicated for the treatment of schizophrenia in adult patients.